A Study of PRP Treatment for Hair Loss after Cancer Therapy in Women with Breast Cancer

Share
Print

Full Title

A Pilot Study of the Clinical Effectiveness of Platelet-Rich Plasma (PRP) for the Treatment of Endocrine Therapy-Induced Alopecia (EIA) and Permanent Chemotherapy-Induced Alopecia (pCIA) in Breast Cancer Patients

Purpose

Some hormonal treatments and chemotherapy used to treat breast cancer can cause partial or complete hair loss. This hair loss can be minimized with “cold cap” usage during breast cancer treatment or with certain medications or a hair transplant after treatment. If these treatments don’t work, there are not many proven alternative options.

Platelet-rich plasma (PRP) is a treatment in which platelets (blood-clotting cells) and plasma (the liquid part of blood) are separated from a small amount of blood, concentrated, and given back to the patient. PRP is used in sports medicine to speed healing of injured tissue, as well as in certain dental and plastic surgery procedures. In this study, researchers want to determine if PRP is useful and safe for treating hair loss after cancer therapy in women treated for breast cancer.

Patients will have a small sample of blood removed, treated, and the plasma separated and injected back into one side of the scalp every 4 weeks, for a total of three treatments. Researchers will see how the treated side of the scalp differs from the untreated side. If it looks like the PRP is helping, a patient may also receive injections into the other (untreated) side of the scalp.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must be women with hair loss following hormonal therapy (tamoxifen, toremifene, anastrozole, letrozole, exemestane, or leuprolide) or chemotherapy for breast cancer.
  • The hair loss must persist despite treatment with minoxidil or spironolactone (hair loss medications).
  • Patients may not have previously received a hair transplant.
  • This study is for women age 18-60.

For more information about this study and to inquire about eligibility, please contact Dr. Anthony M. Rossi at 646-888-6022.

Protocol

20-133

Phase

Pilot

Disease Status

Newly Diagnosed

Investigator

Co-Investigators